AAAAAA

   
Results: 1-13 |
Results: 13
USING THE NATIONAL-CANCER-INSTITUTE ANTICANCER DRUG SCREEN TO ASSESS THE EFFECT OF MRP EXPRESSION ON DRUG-SENSITIVITY PROFILES
Authors: ALVAREZ M ROBEY R SANDOR V NISHIYAMA K MATSUMOTO Y PAULL K BATES S FOJO T
Citation: M. Alvarez et al., USING THE NATIONAL-CANCER-INSTITUTE ANTICANCER DRUG SCREEN TO ASSESS THE EFFECT OF MRP EXPRESSION ON DRUG-SENSITIVITY PROFILES, Molecular pharmacology, 54(5), 1998, pp. 802-814
IDENTIFICATION OF COMPOUNDS WITH PREFERENTIAL INHIBITORY ACTIVITY AGAINST LOW-NM23-EXPRESSING HUMAN BREAST-CARCINOMA AND MELANOMA CELL-LINES
Authors: FREIJE JMP LAWRENCE JA HOLLINGSHEAD MG DELAROSA A NARAYANAN V GREVER M SAUSVILLE EA PAULL K STEEG PS
Citation: Jmp. Freije et al., IDENTIFICATION OF COMPOUNDS WITH PREFERENTIAL INHIBITORY ACTIVITY AGAINST LOW-NM23-EXPRESSING HUMAN BREAST-CARCINOMA AND MELANOMA CELL-LINES, Nature medicine, 3(4), 1997, pp. 395-401
P-GLYCOPROTEIN SUBSTRATES AND ANTAGONISTS CLUSTER INTO 2 DISTINCT GROUPS
Authors: SCALA S AKHMED N RAO US PAULL K LAN LB DICKSTEIN B LEE JS ELGEMEIE GH STEIN WD BATES SE
Citation: S. Scala et al., P-GLYCOPROTEIN SUBSTRATES AND ANTAGONISTS CLUSTER INTO 2 DISTINCT GROUPS, Molecular pharmacology, 51(6), 1997, pp. 1024-1033
REDUCED FOLATE CARRIER GENE (RFC1) EXPRESSION AND ANTIFOLATE RESISTANCE IN TRANSFECTED AND NONSELECTED CELL-LINES
Authors: MOSCOW JA CONNOLLY T MYERS TG CHENG CC PAULL K COWAN KH
Citation: Ja. Moscow et al., REDUCED FOLATE CARRIER GENE (RFC1) EXPRESSION AND ANTIFOLATE RESISTANCE IN TRANSFECTED AND NONSELECTED CELL-LINES, International journal of cancer, 72(1), 1997, pp. 184-190
REDUCTASE ENZYME EXPRESSION ACROSS THE NATIONAL-CANCER-INSTITUTE TUMOR-CELL LINE PANEL - CORRELATION WITH SENSITIVITY TO MITOMYCIN-C AND E09
Authors: FITZSIMMONS SA WORKMAN P GREVER M PAULL K CAMALIER R LEWIS AD
Citation: Sa. Fitzsimmons et al., REDUCTASE ENZYME EXPRESSION ACROSS THE NATIONAL-CANCER-INSTITUTE TUMOR-CELL LINE PANEL - CORRELATION WITH SENSITIVITY TO MITOMYCIN-C AND E09, Journal of the National Cancer Institute, 88(5), 1996, pp. 259-269
REDUCTASE ENZYME EXPRESSION ACROSS THE NATIONAL-CANCER-INSTITUTE TUMOR-CELL LINE PANEL - CORRELATION WITH SENSITIVITY TO MITOMYCIN-C AND EO9 - RESPONSE
Authors: WORKMAN P FITZSIMMONS SA GREVER M PAULL K CAMALIER R LEWIS AD
Citation: P. Workman et al., REDUCTASE ENZYME EXPRESSION ACROSS THE NATIONAL-CANCER-INSTITUTE TUMOR-CELL LINE PANEL - CORRELATION WITH SENSITIVITY TO MITOMYCIN-C AND EO9 - RESPONSE, Journal of the National Cancer Institute, 88(16), 1996, pp. 1161-1163
OXALIPLATIN, TETRAPLATIN, CISPLATIN, AND CARBOPLATIN - SPECTRUM OF ACTIVITY IN DRUG-RESISTANT CELL-LINES AND IN THE CELL-LINES OF THE NATIONAL-CANCER-INSTITUTE ANTICANCER DRUG SCREEN PANEL
Authors: RIXE O ORTUZAR W ALVAREZ M PARKER R REED E PAULL K FOJO T
Citation: O. Rixe et al., OXALIPLATIN, TETRAPLATIN, CISPLATIN, AND CARBOPLATIN - SPECTRUM OF ACTIVITY IN DRUG-RESISTANT CELL-LINES AND IN THE CELL-LINES OF THE NATIONAL-CANCER-INSTITUTE ANTICANCER DRUG SCREEN PANEL, Biochemical pharmacology, 52(12), 1996, pp. 1855-1865
IDENTIFICATION OF A NOVEL INHIBITOR (NSC-665564) OF DIHYDROOROTATE DEHYDROGENASE WITH A POTENCY EQUIVALENT TO BREQUINAR
Authors: CLEAVELAND ES ZAHAREVITZ DW KELLEY JA PAULL K COONEY DA FORD H
Citation: Es. Cleaveland et al., IDENTIFICATION OF A NOVEL INHIBITOR (NSC-665564) OF DIHYDROOROTATE DEHYDROGENASE WITH A POTENCY EQUIVALENT TO BREQUINAR, Biochemical and biophysical research communications, 223(3), 1996, pp. 654-659
EUKARYOTIC DNA TOPOISOMERASES MEDIATED DNA CLEAVAGE INDUCED BY A NEW INHIBITOR - NSC-665517
Authors: GUPTA M ABDELMEGEED M HOKI Y KOHLHAGEN G PAULL K POMMIER Y
Citation: M. Gupta et al., EUKARYOTIC DNA TOPOISOMERASES MEDIATED DNA CLEAVAGE INDUCED BY A NEW INHIBITOR - NSC-665517, Molecular pharmacology, 48(4), 1995, pp. 658-665
GENERATION OF A DRUG-RESISTANCE PROFILE BY QUANTITATION OF MDR-1 P-GLYCOPROTEIN IN THE CELL-LINES OF THE NATIONAL-CANCER-INSTITUTE ANTICANCER DRUG SCREEN/
Authors: ALVAREZ M PAULL K MONKS A HOSE C LEE JS WEINSTEIN J GREVER M BATES S FOJO T
Citation: M. Alvarez et al., GENERATION OF A DRUG-RESISTANCE PROFILE BY QUANTITATION OF MDR-1 P-GLYCOPROTEIN IN THE CELL-LINES OF THE NATIONAL-CANCER-INSTITUTE ANTICANCER DRUG SCREEN/, The Journal of clinical investigation, 95(5), 1995, pp. 2205-2214
SITE OF ACTION OF 2 NOVEL PYRIMIDINE BIOSYNTHESIS INHIBITORS ACCURATELY PREDICTED BY THE COMPARE PROGRAM
Authors: CLEAVELAND ES MONKS A VAIGROWOLFF A ZAHAREVITZ DW PAULL K ARDALAN K COONEY DA FORD H
Citation: Es. Cleaveland et al., SITE OF ACTION OF 2 NOVEL PYRIMIDINE BIOSYNTHESIS INHIBITORS ACCURATELY PREDICTED BY THE COMPARE PROGRAM, Biochemical pharmacology, 49(7), 1995, pp. 947-954
NEW ANTINEOPLASTIC AZA-PHOSPHOLIPIDS - SYNTHESIS, IN-VITRO CYTOTOXICITY AND DIFFERENTIAL CELLULAR-SENSITIVITY AGAINST 70 HUMAN TUMOR-CELL LINES
Authors: PRINCIPE P BROQUET C PAULL K GREVER MR COULOMB H HUCHET M MENCIAHUERTA JM BRAQUET P
Citation: P. Principe et al., NEW ANTINEOPLASTIC AZA-PHOSPHOLIPIDS - SYNTHESIS, IN-VITRO CYTOTOXICITY AND DIFFERENTIAL CELLULAR-SENSITIVITY AGAINST 70 HUMAN TUMOR-CELL LINES, International journal of oncology, 4(1), 1994, pp. 29-36
RHODAMINE EFFLUX PATTERNS PREDICT P-GLYCOPROTEIN SUBSTRATES IN THE NATIONAL-CANCER-INSTITUTE DRUG SCREEN
Authors: LEE JS PAULL K ALVAREZ M HOSE C MONKS A GREVER M FOJO AT BATES SE
Citation: Js. Lee et al., RHODAMINE EFFLUX PATTERNS PREDICT P-GLYCOPROTEIN SUBSTRATES IN THE NATIONAL-CANCER-INSTITUTE DRUG SCREEN, Molecular pharmacology, 46(4), 1994, pp. 627-638
Risultati: 1-13 |